Impact Factor
4.43
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.76
3,269 total citations
h5-index
60
h5 depth signal
Cited share
91.8%
481 of 524
Total citations
3,269
Citation footprint
Metric signal
7.29
External metric anchor
Self-citation
1.7%
55 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
971
United States
611
Japan
283
Germany
240
Italy
131
Citing Fields of Research
Immunology
2,450
Oncology
717
Immunotherapy
646
Lung Cancer
224
Liver & Colon Cancer
135
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
7,593
Articles tracked across the journal lifetime
Indexed publication set
524
481 cited publications
Last 12 months
394
32.8 publications/month
Open access share
100.0%
394 OA publications in the last year
Leading citing country
China
971 citing publications
Leading citing field
Immunology
2,450 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v13n1, 1982-
v13n1, 1982-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Broad Categories
Allergy and Immunology
Neoplasms
Therapeutics
Immunology
MeSH Descriptors
Immunotherapy
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s00262-026-04604-8
Open DOI
A phase I clinical trial of NK510 combined with PD-1 blockade in patients with advanced non-small cell lung cancer
02
DOI 10.1007/s00262-026-04597-4
Open DOI
GSDMB synergizes anti-PD-1 efficacy via Sema7a-mediated CD8+ T Cell infiltration in bladder cancer
03
DOI 10.1007/s00262-026-04600-y
Open DOI
PRKDC orchestrates immune evasion in hepatocellular carcinoma through CSF1/CSF1R-mediated M2 macrophage polarization
04
05
DOI 10.1007/s00262-026-04601-x
Open DOI
B7-H3 promotes triple-negative breast cancer progression by sustaining SP1-dependent HSPA8 expression
06
DOI 10.1007/s00262-026-04594-7
Open DOI
Response to pembrolizumab in metastatic colorectal cancer with microsatellite instability and markedly reduced HLA-I expression suggests NK cell involvement
Despite growing enthusiasm for immunotherapy in cancer treatment, only a few colorectal cancer (CRC) patients experience lasting therapeutic effect. This limited efficacy is likely driven by different tumor-intrinsic resistance mechanism...
07
08
DOI 10.1007/s00262-026-04592-9
Open DOI
High-dose vitamin C augments LPS/IFN-γ-induced M1 macrophage polarization through JAK2-STAT1 activation and promotes anti-PD-1 efficacy in pancreatic cancer
High-dose vitamin C (HDVC) exhibits antitumor and immunomodulatory properties and may enhance the efficacy of immune checkpoint inhibitors (ICIs); however, its ability to reprogram the immunosuppressive tumor microenvironment (TME) in pa...
09
DOI 10.1007/s00262-026-04595-6
Open DOI
Development of TIL therapy for NF1/SWN-related nerve sheath tumors
Effective therapies remain limited for neurofibromatosis type 1 (NF1)- and schwannomatosis (SWN)-related nerve sheath tumors, particularly for malignant peripheral nerve sheath tumors (MPNSTs). Although tumor-infiltrating lymphocyte (TIL...
10
DOI 10.1007/s00262-026-04585-8
Open DOI
Allogeneic anti-CD19 CAR-T therapy demonstrates sustained efficacy and manageable safety in post-allo-HSCT relapsed B-ALL with extramedullary disease
Background: Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem-cell transplantation (allo-HSCT), particularly with extramedullary disease (EMD), has a dismal prognosis. The efficacy and durability of...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Continues: Cancer immunology and immunotherapy.
(1988)19890818 Notice published Printed on acid-free paper